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Poster Session II S351Materials and Methods: We retrospectively analyzed all patients
(n 5 64) from January 1, 2009 to December 31, 2009 at our institu-
tion undergoing allogeneic SCT for hematologic malignancies. PLT
refractoriness was defined as a clinical requirement for platelet cross-
matching. Clinical outcomes studied included day 100 and one year
survival, platelet and neutrophil engraftment and acute GVHD inci-
dence. Risks of death and GVHD were compared between groups
with logrank tests and were estimated with the Kaplan-Meier
method. Number of days to platelet or neutrophil engraftment was
compared with the Wilcoxon rank-sum test.
Results: Allogeneic SCT was performed in 64 patients including
three pediatric patients. 10/64 (16%) patients demonstrated PLT re-
fractoriness. Patients with PLT refractoriness had higher risk of
acute GVHD (Grade I-IV) as compared to non refractory patients
(p 5 0.046). Excluding patients without platelet engraftment due
to early death, patients with pretransplant PLT refractoriness (n 5
9) had delayed PLT engraftment, median (IQR) 5 27 days (19.5-
64.50) compared to non-refractory patients (n 5 52), median
(IQR) 5 19 days (16-23) (p 5 0.01). However, there was no signifi-
cant differences in terms of overall survival, GVHD grade II-IV or
time to neutrophil engraftment
Conclusions: PLT refractoriness may be associated with increased
incidence of acute GVHD and delayed platelet engraftment result-
ing in longer platelet transfusion support. A larger study is planned
to confirm these findings.397
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Radiotherapy (RT) is used as an antineoplastic and immunomod-
ulatory therapy prior to allogeneic HCT. The practice of incorpo-
rating RT as part of HCT varies widely across centers worldwide.
The present study explores the use of RT in 14,920 allogeneic
HCT recipients (total body irradiation [TBI], N5 14,696, and total
lymphoid irradiation [TLI], N5 402) reported to the Center for In-
ternational Blood and Marrow Transplant Research between 1995
and 2010. TBI was performed in 335 reporting centers in 42 coun-
tries. The median age of TBI recipients was 33 years and the median
age increased from 31 to 39 years during the period (p\0.0001). TBI
was most commonly use in HCT for acute lymphocytic leukemia
(87%) and in patients with prior central nervous system (CNS) leu-
kemia involvement (76%, p\0.001). Shielding was used in 52% of
patients, commonly for lungs (72%) and eyes (14%). The median
dose of TBI was 12 Gy, with most patients receiving 2 fractions
per day (60%, p\0.0001), for total of 6 doses (34%, p\0.0001).
Myeloablative TBI doses (.8 Gy) decreased from 94% to 63% dur-
ing the period (p\0.001). Conversely, reduced intensity and non-
myeloablative (RI/NMA) TBI doses increased from\1% to 36%
(p\0.001). TBI was most frequently combined with cyclophospha-
mide (97%) in myeloablative regimens and fludarabine (68%) in
RI/NMA regimens. 11% of patients who received TBI also received
RTwithin 14 days of starting conditioning; treatmentwas directed at
the CNS (35%) and gonads (41%). TLI was performed in 70 centers
in 22 countries. The median age for TLI recipients was 37 years and
the median age increased from 29 to 56 years during the period. The
most common indications for TLI was severe aplastic anemia (SAA)
(23%) and acute myeloid leukemia (AML) (19%). TLI for SAA de-
creased from 47% to 0% while TLI for AML increased from 11%to 40% during the period. The median TLI dose was 6 Gy, with
most patients receiving 6 fractions (41%). 4% of patients who re-
ceived TLI also received RTwithin 14 days of starting conditioning;
treatment was most often directed at the spleen (47%). RT practices
in HCT changed during the past 16 years. There was a significant
decrease use of myeloablative TBI and increase in RI/NMA TBI.
Similarly, TLI practices changed towards a RI/NMA approach, be-
ing applied more frequently in older patients for treatment of malig-
nant diseases.
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DCI is administered after AlloHCT to enhance the graft-versus
leukemia effect and thereby induce remission in patients (pts) with
relapsed hematological malignancies. The purpose of this retrospec-
tive study was to identify risk factors for post-DCI progression and
mortality.
We identified 47 pts with hematological malignancies who re-
ceived DCI from 02/1996 to 07/2011 for disease relapse. We ana-
lyzed variables such as pts baseline demographics, malignancy
type, donor relationship, type of AlloHCT, presence of GVHD, du-
ration of post-transplant remission, use of remission induction che-
motherapy prior to DCI and DCI cell dose.
Among pts treated with DCI, 36 (77%) hadmyeloidmalignancies.
Myeloablative regimen was used in 36 pts (77%) and 35 pts (74%)
had HLA-identical sibling donor transplant. 45 pts (96%) had grade
\2 aGVHD and 40 pts (85%) had limited or no cGVHD. Median
time of post-transplant relapse was 6.0 months (range, 0.9-84.6)
and the median time from transplant to DCI therapy was 7.8 months
(range, 2.3- 114). DCI was used once in 89% of pts and it was pre-
ceded with chemotherapy in 35 of 45 pts (78%). Median CD34
and TNC doses for the first DCI were 2.0x106 and 3.9x108 respec-
tively. The rate of post-DCI grade 3-4 aGVHD was 2% vs. 17%
for extensive cGVHD. With a median follow-up of 40.8 months
(range, 2.3-174.1), 38 pts (77%) had died and 29 (62%) relapsed. Re-
lapse was the most common cause of death (n5 25, 69%) after DCI.
Although pts who received unrelated DCI tended to have less post-
DCI relapses (42% vs. 69%), deaths (50% vs. 86%) or fatal events
due to relapse (50% vs. 73%), the numbers were too small to detect
statistically significant differences between groups. Recursive parti-
tioning analysis indicated that pts who had disease relapse within
20 months after transplant (n 5 39) were at higher risk of post-
DCI relapse, worse OS and RFS. Multivariable analysis demon-
strated that a bone marrow cell source was associated with poor
OS (HR 5 2.6; 95% CI 1.3-5.6, p 5 0.01) compared to peripheral
blood, and that post-transplant disease relapse within 20 months
was an adverse predictor for post-DCI relapse (HR 5 5.2; 95% CI
1.2-22.3, p 5 0.025), OS (HR 5 5.5; 95% CI 1.6-18.5, p 5 0.006)
and RFS (HR 5 3.5; 95% CI 1.2-9.9, p 5 0.02).
With long follow-up we demonstrated that disease relapse within
20months of AlloHCTportends poor clinical outcome despiteDCI,
but for patients with longer remission duration, DCI can result in
long-term progression free survival.
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In the German Multicenter ALL Studies, patients (pts) with Ph+
ALL (very high risk, VHR), with high risk ALL (HR), e.g. B lineage
